Copy to clipboard 
Bioventus reported 4Q21 orthopedic sales of $122.1 million, +23.9% vs. 4Q20. For the full year, the company generated $413.2 million in orthopedic sales, +28.6% vs. the prior year.
Bioness and Misonix, both acquired in 2021, helped the company expand into new verticals. Bioventus generated +5% organic growth in the fourth quarter and +19% organic growth for the full year.
Bioventus made another move in the fourth quarter, acquiring Curavisc to bolster its international footprint in the viscosupplement market. The company also expects to acquire CartiHeal by the end of 2022, but that will likely be Bioventus’ last acquisition until all integrations are complete.
Bioventus CEO Ken Reali said, “At this point in time, there are no other acquisitions that we are planning. We’ll continue to build a pipeline of M&A opportunities. But we need to digest what we have in front of us in 2022. With the pending acquisition of CartiHeal, which we’re very excited about, and the integration of Misonix, it’s just a timing thing for us that we need to get beyond. But it doesn’t change our medium-term strategy of continuing to build our customer verticals off both product development and R&D and enhanced M&A.”
The company’s three strategic priorities in the near term are maintaining double-digit growth, completing integrations to leverage enhanced scale and finalizing the acquisition of CartiHeal.
Bioventus provided 2022 revenue guidance in the range of $545 million to $565 million, representing growth between +26.5% to +31.1%.
Orthopedic Sales Data
All orthopedic sales data is provided in USD millions unless otherwise noted. Orthopedic sales and growth rates are estimated on an as-reported basis.
Orthopedic Sales by Segment
| 4Q21 | 4Q20 | $ Chg | % Chg | |
|---|---|---|---|---|
| Orthobiologics | $80.3 | $71.4 | $8.9 | 12.4% |
| Other | $41.9 | $27.2 | $14.7 | 53.9% |
| Total | $122.1 | $98.6 | $23.5 | 23.9% |
| FY21 | FY20 | $ Chg | % Chg | |
|---|---|---|---|---|
| Orthobiologics | $282.5 | $232.5 | $49.9 | 21.5% |
| Other | $130.7 | $88.6 | $42.1 | 47.5% |
| Total | $413.2 | $321.2 | $92.0 | 28.6% |
Orthopedic Sales by Geography
| 4Q21 | 4Q20 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $107.8 | $89.7 | $18.2 | 20.3% |
| OUS | $14.3 | $8.9 | $5.4 | 60.1% |
| Total | $122.1 | $98.6 | $23.5 | 23.9% |
| FY21 | FY20 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $371.7 | $293.7 | $78.0 | 26.6% |
| OUS | $41.5 | $27.5 | $14.0 | 51% |
| Total | $413.2 | $321.2 | $92.0 | 28.6% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $130.4 | |
| Cost of Sales | $42.6 | 32.7% |
| Selling and Admin | $80.9 | 62% |
| R&D | $7.1 | 5.4% |
| Other | $0.4 | 0.3% |
| Net Earnings | ($0.6) | (0.5%) |
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
Bioventus reported 4Q21 orthopedic sales of $122.1 million, +23.9% vs. 4Q20. For the full year, the company generated $413.2 million in orthopedic sales, +28.6% vs. the prior year.
Bioness and Misonix, both acquired in 2021, helped the company expand into new verticals. Bioventus generated +5% organic growth in the fourth quarter and +19%...
Bioventus reported 4Q21 orthopedic sales of $122.1 million, +23.9% vs. 4Q20. For the full year, the company generated $413.2 million in orthopedic sales, +28.6% vs. the prior year.
Bioness and Misonix, both acquired in 2021, helped the company expand into new verticals. Bioventus generated +5% organic growth in the fourth quarter and +19% organic growth for the full year.
Bioventus made another move in the fourth quarter, acquiring Curavisc to bolster its international footprint in the viscosupplement market. The company also expects to acquire CartiHeal by the end of 2022, but that will likely be Bioventus’ last acquisition until all integrations are complete.
Bioventus CEO Ken Reali said, “At this point in time, there are no other acquisitions that we are planning. We’ll continue to build a pipeline of M&A opportunities. But we need to digest what we have in front of us in 2022. With the pending acquisition of CartiHeal, which we’re very excited about, and the integration of Misonix, it’s just a timing thing for us that we need to get beyond. But it doesn’t change our medium-term strategy of continuing to build our customer verticals off both product development and R&D and enhanced M&A.”
The company’s three strategic priorities in the near term are maintaining double-digit growth, completing integrations to leverage enhanced scale and finalizing the acquisition of CartiHeal.
Bioventus provided 2022 revenue guidance in the range of $545 million to $565 million, representing growth between +26.5% to +31.1%.
Orthopedic Sales Data
All orthopedic sales data is provided in USD millions unless otherwise noted. Orthopedic sales and growth rates are estimated on an as-reported basis.
Orthopedic Sales by Segment
| 4Q21 | 4Q20 | $ Chg | % Chg | |
|---|---|---|---|---|
| Orthobiologics | $80.3 | $71.4 | $8.9 | 12.4% |
| Other | $41.9 | $27.2 | $14.7 | 53.9% |
| Total | $122.1 | $98.6 | $23.5 | 23.9% |
| FY21 | FY20 | $ Chg | % Chg | |
|---|---|---|---|---|
| Orthobiologics | $282.5 | $232.5 | $49.9 | 21.5% |
| Other | $130.7 | $88.6 | $42.1 | 47.5% |
| Total | $413.2 | $321.2 | $92.0 | 28.6% |
Orthopedic Sales by Geography
| 4Q21 | 4Q20 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $107.8 | $89.7 | $18.2 | 20.3% |
| OUS | $14.3 | $8.9 | $5.4 | 60.1% |
| Total | $122.1 | $98.6 | $23.5 | 23.9% |
| FY21 | FY20 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $371.7 | $293.7 | $78.0 | 26.6% |
| OUS | $41.5 | $27.5 | $14.0 | 51% |
| Total | $413.2 | $321.2 | $92.0 | 28.6% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $130.4 | |
| Cost of Sales | $42.6 | 32.7% |
| Selling and Admin | $80.9 | 62% |
| R&D | $7.1 | 5.4% |
| Other | $0.4 | 0.3% |
| Net Earnings | ($0.6) | (0.5%) |
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
